The Motley Fool: Moderna’s biotechnology advances are quite promising
The Motley Fool’s Take Some investors might view biotech company Moderna as a shooting star that shone bright for a while, then flamed out. In 2022, it generated sales of nearly $19 billion, but it expects only $4 billion this year. The real story for …